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of treatment modalities have been developed and over-
all results have improved in recent years, mortality rates
of up to 50% and amputation rates of up to 60% are
reported.1,2 Conventional procedures usually encom-
pass prosthetic in situ repair or complete removal of
infected parts of the vessel or the infected prosthesis
and reconstruction with an extra-anatomic bypass graft.
Both techniques are associated with distinct technical
problems and considerable mortality and morbidity
resulting from reinfection and suture line problems
leading to multiple reoperations and prolonged antibiot-
ic treatment.
The use of fresh vascular allografts was first reported
50 years ago.3 However, because of their high rate of
thrombosis, spontaneous rupture, and formation of
anastomotic aneurysm, allografts were considered
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unsuitable to serve as vascular substitutes.4 In recent
years, excellent results in the treatment of infectious
endocarditis have been obtained with cryopreserved
allograft valves.5 In addition, the long-term perfor-
mance of cryopreserved allograft heart valves proved to
be markedly superior to freshly implanted allograft
valves.6 This led us to use cryopreserved arterial allo-
grafts for in situ repair in patients with major vascular
infection.7 Although the initial results were promising,
experience with this new technique is limited7,8 and
direct comparison with conventional surgery has not
been performed. 
We compared the use of cryopreserved arterial allo-
grafts with in situ repair and extra-anatomic recon-
struction using prosthetic material in the treatment of
mycotic aneurysms and infected vascular prostheses of
the thoracic or abdominal aorta that were implanted
between 1990 and 1996 at our institution.
Methods
Patients. Seventy-two patients (Table I) with mycotic
aneurysms (n = 29) or infected vascular prostheses (n = 43)
of the thoracic (n = 26) or abdominal aorta, with (n = 24) or
without (n = 22) pelvic or groin vessel involvement, were
treated either with conventional surgery (n = 38) or with
implantation of a cryopreserved arterial allograft (n = 34).
Median age was 62 years (range 40 to 85 years). Surgery was
performed urgently within 24 hours after admission in 46
patients (64%), within 3 days in 18 (25%), and electively in 8
(11%). Twenty-five patients (35%) had fistulas from the aorta
to different organs: 8 to bronchi, 5 to the esophagus, 11 to
intestines, and 1 to the urinary tract. Forty-six patients (64%)
had previously received antibiotic therapy; of these, 61% had
received multiple antibiotics.
Patients treated by implantation of allografts had more fre-
quent peripheral arterial vascular disease and atrial fibrilla-
tion than the conventionally treated group. In addition,
patients with an allograft were more likely to have had posi-
tive blood culture and to have received antibiotic therapy
before the operation.
Selection of vascular graft. The procurement of arteries
from organ donors and the cryopreservation of vascular seg-
ments similar to the technique used for heart valve allografts
was first started in 1990. Thus availability of cryopreserved
allografts was limited in the early phase of this report.
Although not randomized, the selection of the surgical tech-
nique was dependent only on the presence of a cryopreserved
allograft and not on the preoperative status of the patient.
After 1994, procurement of allografts, subject to the usual
organ donor shortage, became familiar and allografts were
implanted more often than prostheses. Hence patients with
conventional treatment have a median follow-up time of 34
months (range 10 to 84 months), whereas patients with allo-
grafts have a median follow-up time of 24.5 months (range 10
to 83 months) (P > .2). 
Operative technique. The preparation of allografts and the
operative technique have been described in detail.7,9 In brief,
arteries were procured from organ donors who fulfilled heart
valve selection criteria according to the European standards
for cryopreserved heart valve allografts.10 The arteries were
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Table I. Preoperative patient data (1990-1996; n = 72)
Homograft Prosthesis 
No. % No. % P value
Age (yr)
Median 61 63 .8
Range 40 to 85 48 to 81
Mycotic aneurysm 16 47 13 34
Infected vascular prosthesis 18 53 25 66 .3
Thoracic aorta 12 35 14 37
Abdominal aorta 22 65 24 63 .9
Preoperative sepsis 24 71 20 53 .12
Positive blood culture 24 71 10 26 .001
Preoperative antibotic therapy 27 79 13 34 .001
Mycobacterium tuberculosis, 8 24 9 24 .99
fungi, or multidrug-resistant bacteria
Peripheral arterial vascular occlusion 22 65 13 34 .01
Atrial fibrillation 7 21 2 5 .05
Renal insufficiency 6 18 14 37 .07
Chronic obstructive lung disease 20 59 18 47 .3
Diabetes mellitus 10 29 12 32 .8
Serum creatinine (µmol/L) 127 ± 74 127 ± 90 .99
Coronary artery disease 20 59 19 50 .4
Emergency surgery 21 62 27 71 .4
prepared in the European Homograft Bank, Brussels,
Belgium, where they were decontaminated, dipped in ice-
cold cryoprotective solution (10% dimethylsulfoxide), frozen
in liquid nitrogen to –100°C, and stored in the vapor phase of
liquid nitrogen at –180°C. The grafts were thawed immedi-
ately before implantation. 
For infection of the ascending aorta and aortic arch, a
median sternotomy was made; cardiopulmonary bypass, cold
blood cardioplegic solution, and, if indicated, deep hypother-
mic circulatory arrest (16°C) and retrograde cerebral perfu-
sion were used. The descending aorta was approached
through a left posterior thoracotomy. Partial venoarterial
bypass at moderate hypothermia (30°C) was instituted via the
left groin vessels. A standard midline incision was made in
patients with mycotic aneurysms of the abdominal aorta and
a retroperitoneal approach was used to replace infected
infrarenal prosthetic grafts. 
Mycotic aneurysms or infected grafts were excised, and the
allografts were inserted end to end to the normal aorta with
the use of single, running polypropylene sutures. Extended
periaortic, perigraft, mediastinal, or chest wall debridement
was not performed. Neither viable tissue such as omentum or
muscle flaps nor autologous arteries or veins were used; if but-
tressing was necessary, additional allograft tissue was used. 
The conventional surgical techniques comprised in situ
reconstruction (n = 20) with a new vascular prosthesis or
removal of infected vascular sections or graft material togeth-
er with extra-anatomic bypass grafting (n = 18).
Intraoperative findings. Despite the higher incidence of
preoperative antibiotic therapy, pus was visible during the
operation in 11 patients (32%) in the allograft group but in
only 4 patients (11%) in the conventional surgery group (P =
.04). The types of infectious agents could be identified in 59
patients (82%) and did not differ between the 2 groups. In 13
of 59 patients (22%), 2 or more responsible agents could be
found (Table II). Fistulas from the aorta to esophagus,
bronchi, bowels, and urinary tract were equally frequent,
35% in the allograft group and 34% in the conventional
surgery group. 
Patients in the allograft group were more likely to receive
bi-iliac anastomoses, 17 of 22, whereas 17 of 24 patients in
the conventionally treated group had extra-anatomic bypass
grafts requiring bifemoral anastomoses (P = .001).
Clinical assessment and follow-up. Medical history was
derived from reports from the referring hospitals and our
institution. Blood cultures were taken and the usual hemato-
logic and clinical indices of infection were determined before
and after the operations. Intraoperatively, appropriate culture
media for aerobes, anaerobes, fungi, and mycobacteria were
taken. Location and extent of infection, as well as presence of
fistulas, were noted. Rapid Gram staining was performed in
all. Duration of artificial respiration, time in intensive care,
hospitalization, and the postoperative use of antibiotic thera-
py were assessed and cumulatively calculated for the entire
follow-up time. In addition, perioperative mortality (mortali-
ty within 30 days after the operation or within the same hos-
pitalization), disease-related survival, and survival free from
reoperation were assessed. Disease-related survival was
defined as survival free from perioperative death or death
during follow-up resulting from recurrence of infection, reop-
eration, or graft-related complications. Patients were fol-
lowed up yearly by the referring physician, the referring hos-
pital, and/or by our institution. At the end of follow-up, 87%
of patients treated by implantation of allografts were fol-
lowed up by magnetic resonance imaging angiography (n =
15), computed tomography (n = 7), conventional angiography
(n = 7), or transesophageal echocardiography (n = 7). 
In addition, approximate costs per patient for the operation,
anesthesia, hospitalization, and antibiotic therapy were
cumulatively calculated, time-adjusted for the differences in
follow-up, and compared between the two groups per day of
hospitalization. Immunohistochemical examinations of ex-
planted allografts were available in 3 of 4 patients who had died.
Postoperative antibiotic treatment. Patients with allo-
grafts received postoperative intravenous antibiotic treatment
for 4 to 6 weeks, based on the experience gained with the use
of cryopreserved valve allografts in the treatment of aortic
valve endocarditis.11 In addition, patients with difficult-to-
treat infectious agents, eg, mycobacteria or fungi, had oral
antibiotics for 3 months (n = 6). None of the patients received
long-term or life-long antibiotic treatment.
Patients with conventional surgical therapy were treated
with intravenous antibiotics for 6 weeks, followed by oral
antibiotics for 3 months in case of negative and 6 months in
case of positive arterial wall culture findings.12 For high-risk
patients oral suppressive antibiotics were recommended
indefinitely (n = 4).13 For statistical purposes, indefinite post-
operative antibiotic treatment was defined as treatment for
365 days.
Explant studies. Explanted cryopreserved allografts were
studied by macroscopic, histologic, and immunohistochemi-
cal examinations. Hematoxylin-eosin and van Gieson elastin
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 6
Vogt et al   967
Table II. Frequency of responsible infectious agents
in patients with major vascular infection (1990-1996;
n = 72)
Infectious agent Homograft Prosthesis
Staphylococcus aureus 12 10
Staphylococcus, coagulase negative 5 3
Streptococcus pneumoniae 1 5
Pseudomonas aeruginosa 1 3
Enterococcus 1 2
Escherichia coli 2 4
Candida albicans 3 —
Candida parapsilosis 1 2
Aspergillus fumigatus 2 —
Mycobacterium tuberculosis 2 —
Propionibacterium acnes 1 5
Salmonella typhii 3 —
Treponema pallidum* — 2
*Treponema pallidum was detectable in aortic tissue; both patients had con-
comitant superinfection with coagulase-negative Staphylococcus.
stains were used. Gram staining was used to detect bacterial
invasion. Immunohistochemical techniques were performed
to differentiate inflammatory cells: CD45 for leukocytes,
CD45RO, CD3, and CD43 for T-cell lymphocytes, CD20 for
B-cell lymphocytes, and CD68 for macrophages. Results
were compared with immunohistochemical examinations of
nonimplanted and explanted cryopreserved valve and vascu-
lar allografts.9,11
Statistical analyses. Data are presented as median (range)
and as frequencies (percent). Categorical data were assessed
by means of the Pearson c 2 test or Fisher’s exact test to com-
pare preoperative patient data and postoperative complications
of all patients unrelated to the follow-up time. Continuous data
were compared by means of the Mann-Whitney U test and
were time-adjusted per year of survival. Disease-related sur-
vival, survival free of reoperation, and the persistence of com-
plete elimination of infection were calculated by means of
Kaplan-Meier analysis; the log-rank test was used to compare
groups. Hazard ratio for disease-related survival and disease-
related survival free of reoperation was assessed by univariate
Cox regression analysis adjusting dissimilarities between the
2 groups. The assumption of proportional hazards was
assessed graphically by log minus log survival plots. A step-
wise Cox regression analysis was performed to assess inde-
pendent predictors of outcome including all preoperative
patient data (Table I) differing between groups by at least P <
.1. All calculations were performed with the use of the statis-
tical package SPSS for Windows 6.0 (SPSS, Inc, Chicago, Ill).
Results
Mortality, survival, and reoperation. Nine deaths
occurred in the perioperative period, 7 in the prosthesis
group (18%) and 2 in the allograft group (6%). The 30-
day mortality tended to be lower in the group treated by
allografts (P = .15) because of the lower perioperative
morbidity (Table III), as discussed below. During the fol-
low-up time, 3 patients in the allograft and 2 in the con-
ventional surgery group died of causes unrelated to infec-
tion, surgery, or vascular grafts and 2 patients in each
group were lost to follow-up, all patients being free of
infection at the latest time of contact. Including perioper-
ative deaths, there were 4 disease-related deaths in the
allograft group (12%) and 12 in the conventional surgery
group (32%) during the entire period of observation.
Thus for the conventional surgery group the hazard ratio
for disease-related death, adjusted for dissimilarities
between groups, was 10.2 (95% CL 3.3–24.3; P = .008).
In addition, conventionally treated patients had a worse
disease–related survival free of reoperation (29% ± 9%
vs 79% ± 7%) (Fig 1), with an adjusted hazard ratio for
disease-related reoperation during the follow-up time of
16.8 (95% CL 6.8–38.3; P = .0001) (Table III). 
To determine whether operative technique was an
independent predictor for disease-related survival free
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Table III. Postoperative course in patients with major vascular infection (1990-1996; n = 72)
Homograft Prosthesis 
No. % No. % P value
Thirty-day mortality 2 6 7 18 .12*
Total surgery or infection-related mortality 4 12 12 32 .008†
Reoperation 3 9 17 45 .001†
Infection completely eliminated 31 91 20 53 .001‡
Postoperative sepsis 6 18 15 40 .05*
Tracheotomy required 2 6 10 26 .05*
Postoperative hemofiltration 1 3 10 26 .01*
Secondary wound closure 3 9 16 43 .005*
Time on respirator postoperatively (d)§
Median 0.4 4.5
Range 1-28 2-60 .001||
Time in intensive care unit (d)§
Median 1 11
Range 1-42 2-120 .002||
Duration of hospitalization (d)§
Median 14 30
Range 7-150 15-240 .02||
Duration of postoperative antibiotic therapy§
Median 21 40
Range 21-90 60-365 .002||
*Two-tailed Fisher’s exact test.
†Cox regression analysis, adjusted for dissimilarities between the 2 groups.
‡Kaplan-Meier analysis.
§Cumulative duration per year of follow-up.
||Mann-Whitney U test, adjusted per year of follow-up.
of reoperation, we introduced preoperative patient data
(Table I), differing by a P value < .1, into multivariable
Cox regression analysis (Table IV). Surgical technique
proved the most important risk factor for reoperation
(hazard ratio 4.03; 95% CL 1.63-9.92; P = .005). The
number of infected grafts was the only other variable
independently related to this end point (hazard ratio
1.34; 95% CL 1.05-1.72; P = .05).
Morbidity. For the entire period of observation, the
cumulative duration of artificial ventilation, the time in
the intensive care unit, and the duration of hospitaliza-
tion and antibiotic treatment, time-adjusted per year of
survival, were shorter in the allograft group than in the
group treated by conventional surgery (Table III). The
cumulative incidence of sepsis, need for tracheotomy,
hemofiltration, and secondary wound closure were
lower in the allograft group, whereas the percentage of
persistence of infection was higher in the conventionally
treated group (P = .001).
Fate of the allograft. Two late allograft-related deaths
occurred 10 and 18 months after implantation. Both
patients, an 86-year-old man and an 83-year-old woman,
died of an allograft-duodenal fistula with evidence of
persistent Candida albicans infection in 1. Neither allo-
graft aneurysm, perivascular exudation, unusual scar for-
mation, nor intraluminal mural thrombi could be detect-
ed during the follow-up time. One patient had
progressive stenosis of an allograft at the descending
thoracic aorta after 18 months, which was successfully
relieved by percutaneous vascular stent placement. 
Immunohistochemical examinations. Explanted
cryopreserved allografts were acellular and nonvital,
with total desquamation of the endothelial layer, and all
showed nonspecific low-grade inflammation and B-cell
lymphocyte infiltration. Macrophages or Langerhan’s
cells could not be found in explanted allografts, and T-
cell lymphocytes were identified in only 1. The colla-
gen framework and the glucose-amino-glycan matrix
was intact in all, whereas the elastic fibers of the media
were partly fragmented.
Costs. The manufacture of allografts is approximately
as expensive as that of vascular prosthesis. Considering
the charges for anesthesia, surgery, intensive care, use of
antibiotics, and hospitalization, the cumulated median
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Fig 1. Disease-related survival free of reoperation for patients with major vascular infection, treated either by
implantation of cryopreserved arterial homografts or by conventional surgery (1990 to 1996; n = 72).
Table IV. Univariate and multivariable risk factors for infection-related survival free of reoperation in patients
with major vascular infection (1990-1996; n = 72) adjusted for dissimilarities between groups (Table I)
Univariate Multivariable
HR 95% CI P value HR 95% CI P value
Conventional surgery 4.1 1.7-10.0 .005 4 1.6-9.9 .005
Abdominal operation 2.6 1.0-6.4 .05
Mycotic aneurysm 0.3 0.1-0.8 .05
Previous operation 3 1.2-7.3 .05
No. of infected grafts 1.3 1.06-1.6 .05 1.3 1.05-1.7 .05
HR, Hazard ratio; CI, confidence interval.
costs in the conventional surgery group were $392,000
(range $89,000 to $580,000) versus $58,000 (range
$55,000 to $160,000) in the allograft group (P < .001).
Thus the time-adjusted median average was $2000 per
day of follow-up for patients treated by allografts and
$3319 for those treated by conventional surgical tech-
nique (P = .005).
Discussion
The use of cryopreserved arterial allografts provides
a safer, cheaper, and more effective treatment for
mycotic aneurysms and infected vascular prostheses
than conventional surgical techniques. In particular,
patients with persistent infection of a previously
implanted prosthesis benefit from this procedure. 
In situ repair of prostheses is associated with suture
line problems and recurrence of infection,1,2 and re-
mote extra-anatomic bypass grafts have a lower paten-
cy rate than anatomic reconstruction14 and are associat-
ed with the risk of aortic stump blowout.15 Moreover,
despite improvements in surgical techniques and long-
term antibiotic therapy,16,17 the disappointing results in
the treatment of aortic fistulas communicating with the
lung, the bowel, or the esophagus have not improved
consistently in the 40 years since the problem was rec-
ognized.18,19 Hence alternative techniques have been
sought to overcome these shortcomings.
The root replacement technique for destructive aortic
endocarditis, which encompasses the replacement of
the proximal part of the ascending aorta—a combined
valvular and vascular in situ repair—has occasionally
resulted in improved survival, reduced reinfection
rates, and decrease in the requirement for postoperative
antibiotics as compared with the use of mechanical
heart valve prostheses.5,11,20 These findings have awak-
ened interest in the use of cryopreserved arterial allo-
grafts in patients with major vascular infections.
The current study compares for the first time implan-
tation of cryopreserved arterial allografts with in situ
repair and extra-anatomic reconstruction using pros-
thetic material for the treatment of mycotic aneurysms
and infected prosthetic grafts. The results show that the
use of allografts requires fewer reoperations to elimi-
nate the vascular infection, which is associated with a
lower incidence of complications and, hence, shorter
cumulated duration of intensive care, hospitalization,
and antibiotic therapy. Despite the higher preoperative
risk regarding preoperative sepsis, positive blood cul-
tures, incidence of peripheral arterial occlusive disease,
and atrial fibrillation, disease-related survival was high-
er in the allograft group, stressing the effectiveness of
allografts in the eradication of major vascular infection.
Patients with implantation of a vascular prosthesis,
although treated according to the current recommenda-
tions,12,13 had a higher percentage of persistence of
infection during the follow-up despite the lesser extent
of infection and the more extensive use of postopera-
tive antibiotics. In addition, implantation of cryopre-
served arterial allografts was highly cost effective. 
Several reasons may be cited for this improved out-
come. The most important one is that cryopreserved
arterial allografts seem to be resistant to bacterial infec-
tions. Possible explanations for this finding are release
of antibacterial substances by the graft, the physico-
chemical properties of the allograft wall, or responses
by the recipient’s immune system.21 Graft viability
early after implantation may also be important, possibly
allowing antibiotic drugs and immunocompetent cells
to diffuse into the allograft, thereby contributing to the
defense of the vasculature against bacterial invasion of
the arterial wall and the periarterial environment.22,23
In the past, several investigators reported on their
experience with fresh vascular allografts.3,4 Szilagyi
and associates4 found a high complication rate (eg,
spontaneous rupture, thrombosis, and late aneurysm
formation) with fresh vascular allografts. As a result,
their use was abandoned for more than 20 years in
favor of artificial prostheses. The difference between
fresh and cryopreserved arterial allografts may be
explained by several mechanisms.6,24 The breakdown
of freshly implanted allografts is accompanied by a
strong immunologic rejection reaction with infiltration
of plasma cells and macrophages. This reaction gives
rise to progressive degeneration of the elastic fibers and
collagen connective tissue, leading to rarification of the
tissue and necrosis.25 The result is a loss of mechanical
resilience in the freshly implanted allograft accompa-
nied by dilatation, aneurysm formation, and eventually
rupture. Indeed, this is exactly the same mechanism
that leads to aneurysm formation and rupture in the
autologous aorta. A similar course of degeneration is
seen in vascular allografts that have been stored at 4°C
after treatment with antibiotics.6,26 By contrast, cryo-
preserved allografts showed less infiltration with
immunocompetent cells, as supported by our limited
explant studies, substantiating the contention that fresh
allografts are more antigenic than cryopreserved grafts.
Moreover, the addition of a cryoprotectant such as
dimethyl sulfoxide has been demonstrated to further
reduce the antigenicity of allografts.27
In addition, the preservation of the collagen frame-
work, glucose-amino-glycan matrix, and the elastic
fibers of the media seem to form a digestion-resistant
barrier that protects the allograft from autogenic lysis
and renders it relatively immunologically inert, provid-
ing the basis for the greater mechanical strength of cryo-
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preserved as compared with fresh vascular allo-
grafts.28,29 This is consistent with the promising
midterm results of our cryopreserved arterial allografts,
as well as with the observed long-term maintenance of
cryopreserved heart valve allografts.6
In conclusion, the use of cryopreserved arterial allo-
grafts demonstrates an improved disease-related sur-
vival in patients with major vascular infection. Larger
clinical studies and a longer follow-up time are neces-
sary to confirm these results. Even though durability of
allografts is limited, eradication of infection presum-
ably would enable patients to undergo replacement of
the allograft with a prosthesis with a lower risk of rein-
fection at a later time. However, successful initial con-
trol of infection, a prerequisite for survival, is best
achieved with cryopreserved arterial allografts. 
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Discussion
Dr Tirone E. David (Toronto, Ontario, Canada). We are
indebted to Dr Vogt and his associates from Zurich for pre-
senting this information on the management of mycotic
aneurysms and infected Dacron grafts in the thoracic and
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abdominal aorta. Infections in prosthetic grafts are a dreadful
complication of surgery and we should always take all mea-
sures to prevent them. Unfortunately, such complications
occur even in the hands of surgeons who adhere scrupulously
to aseptic techniques. 
Although we have extensive experience with aortic root
abscess in patients with active endocarditis and prosthetic
valve endocarditis, our experience with infection in the
descending thoracic aorta is more limited. We have done only
8 operations in the past 20 years. Three of the patients had
infected grafts and 5 had mycotic aneurysms of the descend-
ing thoracic aorta. I do not like operating on these patients
and hope I never need to again. However, in all 8 of the
patients I operated on, I was able to cure the infection with
conventional surgery. I have never used homografts, as you
have described. 
I firmly believe that extensive debridement of all necrotic
and chronically inflamed material is the most important com-
ponent of these operations. Although we agree that anatomic
reconstruction of the aorta is preferable to extra-anatomic
bypass, this is not possible in every case. At least it was not
possible in all my cases. I was forced to do an extra-anatom-
ic bypass because of the extension of the infection. Finally, in
every one of my cases I used a living patch, such as a muscu-
lar pedicle or omentum, to cover the area that was infected. 
Dr Vogt’s data suggest that use of the aortic homograft is bet-
ter than conventional surgery. That leads me to a few questions. 
Do you believe that the 2 groups of patients are comparable?
Although the number of patients is small for computing statis-
tical differences, the group who had conventional surgery had
a higher preoperative proportion of infected grafts as opposed
to mycotic aneurysms and a higher incidence of preoperative
renal failure—2 major determinants of operative outcomes. 
Second, did you manage to implant the homograft in the
anatomic position in all cases, or did you use the homograft
in the easier cases and simply ligate the aorta and perform an
extra-anatomic bypass in the more complex ones? Those
patients are obviously much sicker than those in whom you
can insert a graft in the anatomic position. 
Last, you showed that the rate of freedom from reoperation
was much higher in the homograft group, but were the
patients similar? Were the reoperations the result of compli-
cations of extra-anatomic bypass? 
Dr. Vogt. Thank you, Dr David, for your kind comments.
During the last 3 to 4 decades, more than 1 generation of vas-
cular surgeons have been involved in the treatment of major
vascular infections. We cannot assume that the extent of the
debridement of necrotic and inflamed material has been their
only problem. I think extensive debridement is important, but
not the only solution for major aortic infection. Other points
help to determine the outcome after vascular infection, such
as the properties of the prosthetic graft compared with the
homograft wall or the local effectiveness of the perioperative
antibiotic treatment on the perigraft space.
Besides the classic aortic stump blowout syndrome, a major
cause of late death, in situ repair with the use of homografts
also prevents reinfection of extra-anatomic bypass grafts,
which occurs in up to 20% of patients. We did not perform any
extra-anatomic bypass grafts during this period of observation
if a homograft was available. Selection of the operative tech-
nique was determined only by the availability of a homograft.
Thus the patients of the 2 groups are comparable.
Moreover, in the group treated with homografts, 18 patients,
mostly referred in the last 2 to 3 years, had persistence of their
vascular infection despite a history of 27 infection-related
operations. All 18 patients became free from infection after 1
operation using cryopreserved vascular homografts.
The use of homografts has several advantages as described.
I think a decrease of the total disease-related mortality has
not yet been proved only because of the small number of
patients. However, the number of reoperations, as well as
overall costs, is effectively reduced. For us, the cryopreserved
arterial homograft is the substitute of choice in the surgical
treatment of major aortic infection.
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